Ethambutol
- Generic Name
- Ethambutol
- Brand Names
- Etibi, Myambutol
- Drug Type
- Small Molecule
- Chemical Formula
- C10H24N2O2
- CAS Number
- 74-55-5
- Unique Ingredient Identifier
- 8G167061QZ
- Background
Ethambutol is a bacteriostatic agent indicated alongside medications such as isoniazid, rifampin, and pyrazinamide in the treatment of pulmonary tuberculosis. Ethambutol was first described in the literature in 1961. It was developed out of a need for therapies active against isoniazid resistant strains of Mycobacterium tuberculosis.
Ethambutol was granted FDA approval on 6 November 1967.
- Indication
Ethambutol is indicated in combination with other anti-tuberculosis drugs in the treatment of pulmonary tuberculosis. Ethambutol is commonly used in combination with isoniazid, rifampin, and pyrazinamide.
- Associated Conditions
- Mycobacterium Avium Intracellulare Complex (MAC), Mycobacterium Infections, Pulmonary Tuberculosis (TB)
Fermented Soybean Supplementation Among Active Pulmonary Tuberculosis Patients With Standard Therapy in Indonesia
- Conditions
- Motor ActivityBody Weight ChangesPulmonary Tuberculosis
- Interventions
- Dietary Supplement: Fermented soybean
- First Posted Date
- 2015-09-18
- Last Posted Date
- 2022-06-21
- Lead Sponsor
- University of Giessen
- Target Recruit Count
- 147
- Registration Number
- NCT02554318
The Optimal Duration of Preoperative Anti-tuberculosis Treatment of Spinal Tuberculosis
- Conditions
- Tuberculosis, Spinal
- Interventions
- First Posted Date
- 2015-06-23
- Last Posted Date
- 2015-06-23
- Lead Sponsor
- Beijing Chest Hospital
- Target Recruit Count
- 400
- Registration Number
- NCT02477852
- Locations
- 🇨🇳
Beijing chest hospital, Beijing, Beijing, China
PK Study of Anti-TB Drugs
- Conditions
- Tuberculosis
- Interventions
- First Posted Date
- 2015-05-29
- Last Posted Date
- 2018-10-03
- Lead Sponsor
- University of Oxford
- Target Recruit Count
- 61
- Registration Number
- NCT02457208
- Locations
- 🇹🇭
Shoklo Malaria Research Unit, Mae Sot, Tak, Thailand
The Evaluation of a Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients With MDR-TB
- Conditions
- MDR-TB
- Interventions
- Drug: Regimen A locally-used WHO-approved MDR-TB regimen (2011 guideline)
- First Posted Date
- 2015-04-06
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- IUATLD, Inc
- Target Recruit Count
- 588
- Registration Number
- NCT02409290
- Locations
- 🇪🇹
Armauer Hanssen Research Institute, Addis Ababa, Ethiopia
🇪🇹St. Peter's Tuberculosis Specializes Hospital, Addis Ababa, Ethiopia
🇬🇪JSC National Center for Tuberculosis and Lung Diseases, Tbilisi, Georgia
Improving Treatment of Nontuberculous Mycobacterial Infection in Cystic Fibrosis
- Conditions
- Cystic Fibrosis
- Interventions
- First Posted Date
- 2015-02-26
- Last Posted Date
- 2021-02-11
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 31
- Registration Number
- NCT02372383
- Locations
- 🇺🇸
Children's Hospital Colroado, Aurora, Colorado, United States
Assessing PA-824 for Tuberculosis (the APT Trial)
- Conditions
- Pulmonary Tuberculosis
- Interventions
- First Posted Date
- 2014-10-06
- Last Posted Date
- 2023-07-18
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 157
- Registration Number
- NCT02256696
- Locations
- 🇿🇦
University of Cape Town Lung Institute, Cape Town, South Africa
Phase II Investigation of Antimycobacterial Therapy on Progressive, Pulmonary Sarcoidosis
- Conditions
- Sarcoidosis; Antimycobacterial Therapy
- Interventions
- First Posted Date
- 2013-12-31
- Last Posted Date
- 2020-07-09
- Lead Sponsor
- Vanderbilt University
- Target Recruit Count
- 97
- Registration Number
- NCT02024555
- Locations
- 🇺🇸
Ohio State University, Columbus, Ohio, United States
🇺🇸Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸Vanderbilt University School of Medicine, Nashville, Tennessee, United States
Linezolid Instead of Ethambutol in Treatment of Drug-susceptible Tuberculosis
- Conditions
- Pulmonary Tuberculosis Without Resistance to Rifampicin
- Interventions
- First Posted Date
- 2013-11-25
- Last Posted Date
- 2014-12-30
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 429
- Registration Number
- NCT01994460
- Locations
- 🇰🇷
Seoul National University Bundang Hospital, Seongnam, Kyunggi, Korea, Republic of
🇰🇷National Medical Center, Seoul, Korea, Republic of
🇰🇷SMG-SNU Boramae Medical Center, Seoul, Korea, Republic of
Evaluation of SQ109, High-dose Rifampicin, and Moxifloxacin in Adults With Smear-positive Pulmonary TB in a MAMS Design
- Conditions
- Tuberculosis, Pulmonary
- Interventions
- Dietary Supplement: pyridoxine
- First Posted Date
- 2013-02-07
- Last Posted Date
- 2017-09-20
- Lead Sponsor
- Michael Hoelscher
- Target Recruit Count
- 365
- Registration Number
- NCT01785186
- Locations
- 🇿🇦
The Aurum Institute for Health Research, Johannesburg, South Africa
🇿🇦University of Cape Town, Centre for Tuberculosis Research Innovation, Cape Town, South Africa
🇹🇿NIMR - Mbeya Medical Research Programme, Mbeya, Tanzania
Rifampin-Based Tuberculosis Treatment Versus Rifabutin-Based Tuberculosis Treatment in Persons With HIV
- Conditions
- HIV InfectionTuberculosis
- Interventions
- Drug: Standard-dose Lopinavir/RitonavirDrug: Double-dose Lopinavir/Ritonavir
- First Posted Date
- 2012-05-18
- Last Posted Date
- 2018-02-13
- Lead Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
- Target Recruit Count
- 71
- Registration Number
- NCT01601626
- Locations
- 🇵🇪
Asociacion Civil Impacta Salud y Educacion - Miraf CRS (11301), Lima, Peru
🇧🇷Instituto de Pesquisa Clinica Evandro Chagas (12101), Rio de Janeiro, Brazil
🇭🇹Les Centres GHESKIO CRS (30022), Port-au-Prince, Haiti
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.